Lisette Binkhorst
Rotterdam, ZH, Netherlands
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Journal: Pharmaceutical research
Published: July 11, 2019
Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch.
Journal: Clinical pharmacokinetics
Published: October 09, 2015
Circadian variation in tamoxifen pharmacokinetics in mice and breast cancer patients.
Journal: Breast cancer research and treatment
Published: February 24, 2015
Relationship Between Sunitinib Pharmacokinetics and Administration Time: Preclinical and Clinical Evidence.
Journal: Clinical pharmacokinetics
Published: February 04, 2015
Individualization of tamoxifen therapy: much more than just CYP2D6 genotyping.
Journal: Cancer treatment reviews
Published: December 08, 2014
Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen.
Journal: British journal of clinical pharmacology
Published: December 13, 2013
Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen.
Journal: Breast cancer research and treatment
Published: April 12, 2013
Individualization of tamoxifen treatment for breast carcinoma.
Journal: Clinical pharmacology and therapeutics
Published: August 23, 2012
Effects of CYP induction by rifampicin on tamoxifen exposure.
Journal: Clinical pharmacology and therapeutics
Published: May 24, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026